Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 244
Tipo Título / Nombre Autor(es) Año
COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330) Ravandi F, Lancet J..., Bergua Burgues JM 2023
Feasibility and outcome after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia. Results of the BURKIMAB14 trial Ribera JM, Morgades M, García Calduch O..., Bergua Burgues JM 2023
Midostaurin plus 7+3 or Quizartinib plus 7+3 in FLT3-ITD mutated AML Torno M, Día Beya M, Fenández Moreno A..., Bergua Burgues JM 2023
Incidence, risk factors and outcomes od second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience Sobas M, Knopinska-Posluszny W, Bergua Burgues JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P 2023
Update results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: Azacitidine or low-dose Cytarabline with Venetoclax and Quizartinib Bergua Burgués JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P 2023
Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild- type AML Montesinos P, Rodríquez-Veiga R, Bergua Burgues JM, Algarra L..., Labrador J 2023
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO Martín García-Sancho A, Baile M, Dlouhy I, Sancho JM..., Bergua J 2023
Safety and efficacy of tafasitamab ± lenalidomide added to first-line R?CHOP for DLBCL: Phase 1b First-MIND study Belada D, Kopeckova K, Bergua Burgués JM, Stevens D, André M, Pérez Persona E, Pichler P, Staber PB, Trn?ný M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS 2023
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry Bernal T, Fernández Moreno A, LaIglesia A de, Benavente C..., Bergua Burgués JM 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E..., Bergua J, PETHEMA cooperative study group 2023